Clinical Trial

Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 12, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This single-center prospective cohort study aims to evaluate the efficacy and safety of Intensifying treatment with Venetoclax along with intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia (AML) except acute promyelocytic leukemia (non-APL) and exhibiting lower early peripheral blast clearance rate (EPBCR) after standard Intensive Induction therapy (3+7 regimen).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-14; most recent amendment 2024-11-10.
Status change: Not Yet Recruiting → Recruiting 2024-11-10
Trial Details
NCT Number NCT06643962
Lead Sponsor Affiliated Hospital of Nantong University
Conditions Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
Enrollment 83 participants
Start Date 2024-10-31
Primary Completion 2025-12-31 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-12